about
Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial.Clinical review: Biomarkers of acute kidney injury: where are we now?Xenobiotic metabolism: the effect of acute kidney injury on non-renal drug clearance and hepatic drug metabolismUsing drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?Renohepatic crosstalk: does acute kidney injury cause liver dysfunction?The effects of acute renal failure on drug metabolism.Do statins prevent acute kidney injury?Temperature measurement: comparison of non-invasive methods used in adult critical care.The interpretation of brain natriuretic peptide in critical care patients; will it ever be useful?New insights into the glucose oxidase stick test for cerebrospinal fluid rhinorrhoea.Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.Selective decontamination of the digestive tract: time to implement it in all UK intensive care units? Maybe not yet.Glucose homeostasis across human airway epithelial cell monolayers: role of diffusion, transport and metabolism.Factors determining the appearance of glucose in upper and lower respiratory tract secretions.Effect of hyperglycaemia on glucose concentration of human nasal secretions.Surgical face masks are effective in reducing bacterial contamination caused by dispersal from the upper airway.Laboratory investigation of anaphylaxis: not as easy as it seems.Cerebral blood flow and metabolism in patients with chronic liver disease undergoing orthotopic liver transplantation.Hyperglycaemia and the lung.The effect of N-acetylcysteine on oxygen transport and uptake in patients with fulminant hepatic failure.Scaling beta-lactam antimicrobial pharmacokinetics from early life to old ageUsing tramadol to measure CYP2D6 metabolism in critically ill adultsEnd-of-life care in patients with end-stage renal diseaseWhat should we be doing about fungal infections in intensive care?
P50
Q35107640-23B87596-D9DA-4408-9F27-8A9847A454ABQ36928048-A72B4F9F-D282-4C31-8E01-C2BC5AB1F256Q37645239-BEAD5E0F-E7EC-4380-9411-58EDB33ABCBEQ37733572-30E207F6-4458-4E84-A956-06ED514FAFF4Q38107784-697744E4-2F4E-426B-B8CF-6EBC1EA0A319Q38145416-023C6F48-F7C8-4AF6-A0CC-0B37FB4D6E58Q38586166-609D8554-2BC6-4ABA-AF3A-846AB79F12A1Q40510387-78CC9D62-231B-4038-B027-9DA6CB3FB1DEQ42420267-FD675B26-BD8D-4B8A-9608-5C257212FDCDQ43087915-EC1DA82B-E3A9-4EC6-938B-BB0430819B29Q43488121-6984377E-31C0-4E57-98ED-F8CDD3ECBC52Q43525479-EC99D699-ACA6-4FE5-97C5-C092E6609949Q44070435-6876CF6A-BB79-4F6F-9AB6-E32F85FB8FA4Q44675291-8E895960-9691-4EA2-8177-3212C7040014Q44695019-DAA2FBFF-4397-4C6A-B238-8BB7BBCA2180Q45817741-5F3318E4-55E6-4D0A-842D-6B74BE512DF2Q47791144-52F6D85E-C9BD-4DBE-B50C-DBBA7FC6131AQ48537219-DFB1DEA5-4A8A-4377-9B25-9F9097C0A8EEQ51302812-7ED4235A-FE92-4F45-9B4B-0DB7FAF1F66FQ52243716-C3861866-369B-4E90-827F-6F77C0C89E22Q59263334-80B97E8E-FA5E-4561-8D6E-AE96FE0399A1Q62787385-18A0EF16-8117-4ED7-B1AE-DA9DCE14A8B5Q62787436-97538B80-9A15-4430-86D4-09F385001421Q62787452-7000ED15-2843-4269-AE58-8AB34F0F8262
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Barbara Philips
@ast
Barbara Philips
@en
Barbara Philips
@es
Barbara Philips
@nl
Barbara Philips
@sl
type
label
Barbara Philips
@ast
Barbara Philips
@en
Barbara Philips
@es
Barbara Philips
@nl
Barbara Philips
@sl
prefLabel
Barbara Philips
@ast
Barbara Philips
@en
Barbara Philips
@es
Barbara Philips
@nl
Barbara Philips
@sl
P1053
H-1670-2011
P106
P21
P31
P3829
P496
0000-0002-1124-0988